Product Information
ISONIAZID 300 MG TABLET is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $3.4020 per EA under NDC 00555007101. Its NADAC has been published 656 times since Nov 28, 2013.
FDA first approved this application before 1982.
Strength
300 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00555007101
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ISONIAZIDApproval Type
Generic (ANDA)
FDA Application
ANDA080937FDA Approved
Before 1982
On Market Since
9/1/1972
Pharmacological Classes
Price Statistics
The NADAC for ISONIAZID 300 MG TABLET has been published 656 times since Nov 28, 2013, and over the history we have for it it has risen 2032.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.4020 per EA |
|---|---|
| All-time high | $3.5124 (Aug 12, 2026) |
| All-time low | $0.1291 (Jan 17, 2018) |
| 52-week high | $3.5124 |
| 52-week low | $2.6149 |
| Median price | $0.1881 |
| Average price | $0.5119 |
| Largest weekly change | +1311.5% (May 21, 2025) |
| Weeks tracked | 656 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Isoniazid market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Antimycobacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ISONIAZID 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ISONIAZID 300 MG TABLET, manufactured by Teva Pharmaceuticals USA Inc., is $3.4020 per EA (NDC 00555007101), effective Sep 30, 2026.
How has the price of ISONIAZID 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for ISONIAZID 300 MG TABLET has risen 2032.1%. It has been tracked across 656 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ISONIAZID 300 MG TABLET?
Since Nov 28, 2013, the NADAC for ISONIAZID 300 MG TABLET has ranged from a low of $0.1291 (Jan 17, 2018) to a high of $3.5124 (Aug 12, 2026), with a median of $0.1881 per EA.
Are there cheaper alternatives to ISONIAZID 300 MG TABLET?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ISONIAZID 300 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures ISONIAZID 300 MG TABLET?
ISONIAZID 300 MG TABLET (NDC 00555007101) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.